Why the study?
Does amantadine or ribavirin inhibit influenza A virus replication in MDCK cells under low- and high-multiplicity infection conditions?
Does amantadine or ribavirin inhibit influenza A virus replication in MDCK cells under low- and high-multiplicity infection conditions?
In vitro testing of anti-influenza agents against high-multiplicity infections may better predict clinical efficacy than standard low-multiplicity plaque inhibition assays.
The activities of amantadine and ribavirin against influenza A viruses were compared against low-multiplicity (plaque inhibition) and high-multiplicity (protein synthesis inhibition) infections. Our results suggest that the predictive value of in vitro data for the clinic may be improved by consideration of tests against a high-multiplicity infection.
No takes yet. Share an insight, caveat, or question.
Browne et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: